使用Meditec MEL 70G-Scan飞点激光进行的近视准分子原位角膜磨镶术。

Photorefractive keratectomy for myopia with the Meditec MEL 70G-Scan flying spot laser.

作者信息

Nagy Z Z, Fekete O, Süveges I

机构信息

First Department of Ophthalmology, Semmelweis Medical University, Budapest, Hungary.

出版信息

J Refract Surg. 2001 May-Jun;17(3):319-26. doi: 10.3928/1081-597X-20010501-05.

DOI:10.3928/1081-597X-20010501-05

PMID:11383763

Abstract

PURPOSE

To evaluate the efficacy, predictability, stability, and safety of the Meditec MEL 70G-Scan flying spot excimer laser.

METHODS

One hundred thirty myopic eyes were treated with the Aesculap Meditec Mel 70G-Scan ArF flying spot excimer laser with photorefractive keratectomy (PRK). Patient groups: low myopia (Group 1) from -1.50 to -6.00 D (90 eyes), medium myopia (Group 2) from -6.10 to -9.00 D (31 eyes), high myopia (Group 3) from -9.10 to -14.00 D (9 eyes).

RESULTS

At 12 months in the low myopia group, uncorrected visual acuity (UCVA) of 20/40 or better was achieved in 95.5% (86 eyes), 20/20 or better in 77.7% (70 eyes); 2.2% (two eyes) lost two or more lines of best spectacle-corrected visual acuity (BSCVA); 73.3% (66 eyes) were within +/-0.50 D of the target correction and 98.8% (89 eyes) were within +/-1.00 D. In the medium myopia group, UCVA of 20/40 or better was achieved in 74.2% (23 eyes), 20/20 or better in 25.8% (eight eyes); 3.2% (one eye) lost two lines, 61% (19 eyes) were within +/-0.50 D of desired correction and 83.8% (26 eyes) were within +/-1.00 D. In the high myopia group, UCVA of 20/40 or better was achieved in 22.2% (two eyes); 20/25 or better in 11.1% (one eye); none of the eyes achieved 20/20 UCVA; 22.2% (two eyes) lost two lines of BSCVA; 44.4% (four eyes) were within +/-0.50 D and 66.6% (six eyes) were within +/-1.00 D of the target correction. Refractive stability was achieved between 3 and 6 months. Increased intraocular pressure was detected overall in 7.69%.

CONCLUSIONS

The results of predictability, safety, and efficacy in low and medium myopia with the Meditec MEL 70G-Scan flying spot excimer laser were good, but poorer predictability, regression, and a significant loss of BSCVA were observed in the high myopia group.

摘要

目的

评估Meditec MEL 70G-Scan飞点准分子激光的疗效、可预测性、稳定性及安全性。

方法

130只近视眼睛接受了Aesculap Meditec Mel 70G-Scan ArF飞点准分子激光的准分子原位角膜磨镶术（PRK）治疗。患者分组：低度近视（第1组）-1.50至-6.00 D（90只眼），中度近视（第2组）-6.10至-9.00 D（31只眼），高度近视（第3组）-9.10至-14.00 D（9只眼）。

结果

在低度近视组中，12个月时，95.5%（86只眼）的裸眼视力（UCVA）达到20/40或更好，77.7%（70只眼）达到20/20或更好；2.2%（两只眼）最佳矫正视力（BSCVA）下降两行或更多；73.3%（66只眼）在目标矫正值的±0.50 D范围内，98.8%（89只眼）在±1.00 D范围内。在中度近视组中，74.2%（23只眼）的UCVA达到20/40或更好，25.8%（8只眼）达到20/20或更好；3.2%（一只眼）下降两行，61%（19只眼）在预期矫正值的±0.50 D范围内，83.8%（26只眼）在±1.00 D范围内。在高度近视组中，22.2%（两只眼）的UCVA达到20/40或更好；11.1%（一只眼）达到20/25或更好；没有眼睛达到20/20的UCVA；22.2%（两只眼）的BSCVA下降两行；44.4%（四只眼）在目标矫正值的±0.50 D范围内，66.6%（六只眼）在±1.00 D范围内。屈光稳定性在3至6个月时实现。总体上7.69%的患者检测到眼压升高。